phrykt

Incyte Corp (INCY): who owns it and who trades it

As of Nov 16, 2026, INCY insiders reported 49 open-market sales worth $66.1M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Steven H Stein (Vice president), with $35.8M. 8 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Incyte

From the latest filings

Overall: about as much buying as selling. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns INCY

856 funds and institutions reported INCY shares worth $23.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 15.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Baker Bros. Advisors LP15.4%
BlackRock, Inc.9.0%
Dodge & Cox6.0%
Vanguard Capital Management LLC5.5%
State Street Corp4.9%
Vanguard Portfolio Management LLC3.9%
AQR Capital Management LLC2.7%
Geode Capital Management, LLC2.4%
Lsv Asset Management2.1%
Invesco Ltd.2.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP30.76M15.40%$3.5B+0%
BlackRock, Inc.18.03M9.03%$2B-5%
Dodge & Cox11.96M5.99%$1.4B-2%
Vanguard Capital Management LLC11.02M5.52%$1.2B+1%
State Street Corp9.72M4.87%$1.1B+1%
Vanguard Portfolio Management LLC7.79M3.90%$883M+0%
AQR Capital Management LLC5.32M2.66%$603M-8%
Geode Capital Management, LLC4.75M2.38%$537M+1%
Lsv Asset Management4.12M2.06%$467M+5%
Invesco Ltd.4.08M2.04%$463M+5%
Wellington Management Group LLP3.58M1.79%$405M+9%
Renaissance Technologies LLC3.51M1.76%$398M-4%
Morgan Stanley2.95M1.48%$334M+3%
Arrowstreet Capital, Limited Partnership2.74M1.37%$311M-3%
Robeco Institutional Asset Management B.V.2.44M1.22%$277M-3%
Goldman Sachs Group Inc2.31M1.15%$261M-2%
Dimensional Fund Advisors LP2.28M1.14%$259M+15%
Two Sigma Investments, LP2.00M1.00%$227M+382%
Northern Trust Corp1.76M0.88%$200M-5%
Charles Schwab Investment Management Inc1.69M0.85%$192M-2%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, INCY insiders reported $0 of open-market purchases and $66.1M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$66.1M
49 trades, 8 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 6, 2026
Filed Nov 10, 2026

Purchases and sales by month

$28.5M$28.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 6, 2026Steven H SteinCMO & Head of Late-StageSale plan35,042$116.06$4.1MForm 4
Nov 6, 2026Steven H SteinCMO & Head of Late-StageSale plan22,336$117.14$2.6MForm 4
Nov 6, 2026Steven H SteinCMO & Head of Late-StageSale plan60,270$118.27$7.1MForm 4
Nov 6, 2026Steven H SteinCMO & Head of Late-StageSale plan73,969$119.12$8.8MForm 4
Nov 6, 2026Steven H SteinCMO & Head of Late-StageSale plan48,576$119.66$5.8MForm 4
Nov 3, 2026Thomas TrayPrincipal Accounting OffSale plan610$118.96$72.6KForm 4
Oct 15, 2026Pablo J CagnoniPresidentSale plan2,642$112.71$298KForm 4
Sep 15, 2026Pablo J CagnoniPresidentSale plan9,233$120.50$1.1MForm 4
Sep 15, 2026Pablo J CagnoniPresidentSale plan13,985$120.49$1.7MForm 4
Aug 19, 2026Pablo J CagnoniPresidentSale plan10,801$125.56$1.4MForm 4
Aug 12, 2026Pablo J CagnoniPresidentSale plan10,803$120.04$1.3MForm 4
Aug 5, 2026Pablo J CagnoniPresidentSale plan10,640$122.69$1.3MForm 4
Aug 5, 2026Patrick A MayesVice presidentSale plan2,207$123.99$274KForm 4
Aug 3, 2026Patrick A MayesVice presidentSale plan6,055$120.43$729KForm 4
Jul 31, 2026Pablo J CagnoniPresidentSale plan15,888$119.70$1.9MForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan4,695$119.39$561KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan14,661$119.46$1.8MForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan5,332$119.42$637KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan2,187$119.47$261KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan6,171$119.43$737KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan2,864$119.40$342KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan1,643$119.51$196KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan1,642$119.38$196KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan85$122.19$10.4KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan326$121.69$39.7KForm 4
Jul 31, 2026Patrick A MayesVice presidentSale plan2,293$119.41$274KForm 4
Jul 16, 2026Steven H SteinCMO & Head of Late-StageSale plan1,877$114.73$215KForm 4
Jul 16, 2026Mohamed Khairie IssaVice presidentSale plan1,093$115.01$126KForm 4
Jul 15, 2026Steven H SteinCMO & Head of Late-StageSale plan28,237$113.05$3.2MForm 4
Jun 4, 2026Thomas TrayPrincipal Accounting OffSale plan2,639$100.00$264KForm 4
May 26, 2026Thomas TrayPrincipal Accounting OffSale plan2,051$97.35$200KForm 4
May 19, 2026Paul J ClancyDirectorSale plan15,000$94.93$1.4MForm 4
Apr 17, 2026Pablo J CagnoniPresidentSale plan18,667$96.50$1.8MForm 4
Mar 17, 2026Pablo J CagnoniPresidentSale plan18,667$94.24$1.8MForm 4
Feb 19, 2026Pablo J CagnoniPresidentSale plan18,668$100.91$1.9MForm 4
Jan 7, 2026Mohamed Khairie IssaVice presidentSale plan10,856$109.07$1.2MForm 4
Jan 5, 2026Steven H SteinVice presidentSale plan15,634$101.70$1.6MForm 4
Dec 19, 2025Thomas TrayPrincipal Accounting OffSale plan2,774$100.00$277KForm 4
Dec 18, 2025Thomas TrayPrincipal Accounting OffSale plan600$98.25$59KForm 4
Dec 17, 2025Michael James MorrisseyVice presidentSale plan4,323$97.26$420KForm 4
Dec 16, 2025Michael James MorrisseyVice presidentSale plan833$97.42$81.2KForm 4
Dec 16, 2025Michael James MorrisseyVice presidentSale plan53,175$97.29$5.2MForm 4
Dec 11, 2025Patrick A MayesVice presidentSale plan255$94.94$24.2KForm 4
Dec 10, 2025Patrick A MayesVice presidentSale plan5,553$95.58$531KForm 4
Dec 2, 2025Steven H SteinVice presidentSale plan20,105$102.51$2.1MForm 4
Dec 1, 2025Steven H SteinVice presidentSale plan2,559$102.96$263KForm 4
Nov 24, 2025Thomas TrayPrincipal Accounting OffSale plan600$103.00$61.8KForm 4
Nov 21, 2025Thomas TrayPrincipal Accounting OffSale plan169$102.00$17.2KForm 4
Nov 17, 2025Sheila A. DentonVice presidentSale plan278$104.36$29KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Steven H SteinEVP & Chief Medical Officer–$35.8MNov 6, 2026
Pablo J CagnoniPresident, R&D–$14.4MOct 15, 2026
Patrick A MayesEVP & Chief Scientific Officer–$6.6MAug 5, 2026
Michael James MorrisseyEVP, Head of Tech. Operations–$5.7MDec 17, 2025
Paul J ClancyDirector–$1.4MMay 19, 2026
Mohamed Khairie IssaEVP, Head of US Oncology–$1.3MJul 16, 2026
Thomas TrayPrincipal Accounting Officer–$952KNov 3, 2026
Sheila A. DentonEVP & General Counsel–$29KNov 17, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

INCY short interest

Moderate short interest. 5.2% of INCY shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went down 4%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.65M INCY shares were sold short, 5.2% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.6 trading days (days to cover).

Shares short, % of all shares

5.22%May 15Oct 305.87%

Days to cover

5.6May 15Oct 309.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.65M5.22%+6%1.91M5.6
Oct 15, 202610.03M4.95%+0%1.89M5.3
Sep 30, 20269.99M4.93%+0%1.65M6.1
Sep 15, 20269.98M4.92%+7%1.38M7.3
Aug 31, 20269.36M4.62%-0%1.22M7.7
Aug 14, 20269.39M4.63%-8%1.41M6.7
Jul 31, 202610.25M5.06%-3%2.13M4.8
Jul 15, 202610.51M5.26%-1%1.63M6.5
Jun 30, 202610.58M5.30%+0%2.20M4.8
Jun 15, 202610.56M5.29%-7%2.23M4.7
May 29, 202611.40M5.71%+3%1.24M9.2
May 15, 202611.04M5.53%-3%1.28M8.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded INCY

Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 1 sale of INCY. The latest was a sale by Robert P. Bresnahan, Jr. on May 15, 2025, reported May 31, 2025.

Purchases 0Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
May 15, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KSelfMay 31, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Incyte company events

Incyte filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Aug 31, 2026AnnouncementIncyte Corporation today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation. Filing
  3. Jul 28, 2026ResultsReleased financial results. Filing
  4. Jul 6, 2026AnnouncementIncyte Corporation issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. Filing
  5. Jun 22, 2026AnnouncementIncyte Corporation today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura ® (ruxolitinib) cream. Filing
  6. Jun 9, 2026VoteReported shareholder vote results. Filing
  7. Jun 8, 2026AnnouncementIncyte Corporation issued a press release announcing it had entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC. Filing
  8. Apr 28, 2026ResultsReleased financial results. Filing
  9. Mar 30, 2026LeadershipSusanne Schaffert notified Incyte Corporation that she was resigning from the Company’s Board of Directors, effective as of April 15, 2026. Filing
  10. Mar 26, 2026LeadershipIncyte Corporation announced title changes for certain current members of its executive leadership team, effective immediately. Filing
  11. Mar 6, 2026AnnouncementThe U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer in combination with… Filing
  12. Feb 10, 2026ResultsReleased financial results. Filing
  13. Dec 12, 2025LeadershipHervé Hoppenot notified Incyte Corporation that he was retiring from the Company’s Board of Directors, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Incyte financials

Famous investors that hold INCY

8 of the 50 well-known investors we track reported holding INCY in their latest 13F filing. The largest position is Jim Simons's, worth $404M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20263.33M$404M0.5%-5%
Jeremy Grantham · GMOQ3 2026293,623$35.6M0.1%-8%
Ray Dalio · Bridgewater AssociatesQ3 2026203,799$24.7M0.1%+21%
Ken Fisher · Fisher Asset ManagementQ3 2026145,442$17.6M0.0%+6%
Ken Griffin · Citadel AdvisorsQ3 202662,777$7.6M0.0%-56%
Israel Englander · Millennium ManagementQ3 202640,188$4.9M0.0%-51%
Larry Robbins · Glenview Capital ManagementQ3 20265,000$607K0.0%New
Lee Ainslie · Maverick CapitalQ3 20262,489$302K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named INCY in the last 120 days.

FiledHolderFormStake
Nov 12, 2026Dodge & Cox13G/A5.0%
Nov 12, 2026Dodge & Cox13G/A5.0%

Questions about Incyte Corp (INCY) stock

Who owns the most INCY stock?

The largest reported owner of Incyte Corp (INCY) is Baker Bros. Advisors LP, with 15.4% of the company. In total, 856 funds and institutions reported holding INCY at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are INCY insiders buying or selling?

In the last 12 months, INCY insiders reported no open-market purchases and 49 sales worth $66.1M. The latest trade was on Nov 6, 2026. See every trade.

What is the short interest in INCY?

As of Oct 30, 2026, 10.65M INCY shares were sold short, 5.2% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.6 trading days (days to cover). See the history.

Have members of Congress traded INCY?

Yes. 1 member of Congress reported 0 purchases and 1 sale of INCY since Nov 17, 2024. The latest was reported on May 31, 2025. See the trades.

Which famous investors hold INCY?

8 of the 50 well-known investors we track reported INCY in their latest 13F filing, including Jim Simons, Jeremy Grantham, Ray Dalio. The largest position is worth $404M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.